Carbetocin vs. Oxytocin at Elective Cesarean Section

Only registered users can translate articles

The link is saved to the clipboard

StatusRecruiting

Keywords

attention deficit hyperactivity disorder

Abstract

The study investigators are comparing 2 drugs (oxytocin and carbetocin) at 2 different dosages, to help prevent serious bleeding (hemorrhage) after cesarean deliveries. These drugs are used routinely to help contract the uterus and keep it contracted after the delivery of the baby and placenta; this reduces the amount of blood you might lose. At Mount Sinai Hospital, currently oxytocin is used, but its effect on the uterus is much shorter than that of carbetocin. Internationally, there is no consensus as to what the most effective drug to use is and at which dose. The Society of Obstetricians and Gynaecologists of Canada has recently revised its guidelines to suggest 100 micrograms (mcg) of carbetocin as the drug of choice at elective cesarean section. Guidelines from the United Kingdom and the United States currently suggest oxytocin at various doses as the drug of choice at elective cesarean sections. Previous studies at Mount Sinai Hospital have shown that lower doses of oxytocin, 0.35 International Units (IU), and carbetocin, 20 mcg, may be as effective as the higher recommended doses. The investigators plan to conduct a large study to confirm these findings so that they can use the most appropriate dose in the future. Furthermore, the investigators hope to demonstrate that side effects are lower with the lower dose regimens.

Description

Postpartum hemorrhage (PPH) is a major cause of maternal death worldwide. Oxytocin is the most commonly used uterotonic drug to prevent and treat PPH in the world. However, oxytocin has a very short duration of action, requiring a continuous infusion to achieve sustained uterotonic activity. Moreover, large doses are associated with adverse effects like hypotension, nausea, vomiting, dysrhythmias and ST changes. The Society of Obstetricians and Gynecologists of Canada (SOGC) has recommended a single dose of 100 mcg of the longer acting carbetocin at elective cesarean section to promote uterine contraction. In multiple studies performed at Mount Sinai Hospital, we have shown that smaller doses of oxytocin (ED 90 0.35 IU) and carbetocin (ED 90 14.8 mcg) are effective in achieving adequate uterine tone at elective cesarean section. No study has directly compared the high dose regimens with the low dose regimens; therefore a large double-blind randomized controlled trial is necessary to show the non-inferiority of the lower doses of both drugs.

There is a lack of consensus as to what the optimal uterotonic regime is globally. Furthermore, variability in the international guidelines regarding the choice of first line uterotonic in prevention of PPH adds to the confusion. With the widespread availability of carbetocin in some of the developed countries, including Canada, the question of which uterotonic to adopt and at which dose becomes even more difficult to ascertain. Studies that have currently been published suggest the ED90 doses of carbetocin and oxytocin provide adequate uterine contraction with possibly fewer side effects associated with the lower dosed regimens. These advantages may provide a better safety profile and patient satisfaction. To the best of our knowledge, no studies have compared the low doses (ED90) of oxytocin vs. carbetocin, or low (ED90) vs high (conventional) doses of the two drugs in the setting of elective cesarean section. The results of this study will provide evidence on the efficacy and safety of the ED90 dosing compared directly to the higher dosing of both drugs.

Our hypothesis is that the ED90 doses of carbetocin and oxytocin will not be inferior to the higher dosing as determined by the intensity of uterine contraction using a VNRS in women undergoing elective cesarean section. We anticipate that the intensity of uterine contraction using the VNRS at 2 minutes post administration of all drugs will fall within the predetermined margin to signify non-inferiority of all regimens.

Dates

Last Verified:	12/31/2019
First Submitted:	05/22/2017
Estimated Enrollment Submitted:	05/23/2017
First Posted:	05/29/2017
Last Update Submitted:	01/13/2020
Last Update Posted:	01/17/2020
Actual Study Start Date:	05/24/2017
Estimated Primary Completion Date:	05/31/2020
Estimated Study Completion Date:	05/31/2020

Condition or disease

Postpartum Hemorrhage

Intervention/treatment

Drug: Carbetocin

Drug: Oxytocin

Phase

Arm Groups

Arm	Intervention/treatment
Active Comparator: Carbetocin 20mcg Carbetocin 20mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
Active Comparator: Carbetocin 100mcg Carbetocin 100mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
Active Comparator: Oxytocin 0.5IU Oxytocin 0.5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
Active Comparator: Oxytocin 5IU Oxytocin 5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.

Eligibility Criteria

Ages Eligible for Study	18 Years To 18 Years
Sexes Eligible for Study	Female
Accepts Healthy Volunteers	Yes
Criteria	Inclusion Criteria: - Elective cesarean section under spinal anesthesia. - Written informed consent to participate in this study. - Full-term pregnancy - Non labouring patients Exclusion Criteria: - Refusal to give written informed consent. - Allergy or hypersensitivity to carbetocin or oxytocin. - Labouring patients - Need for general anesthesia - Conditions that predispose to uterine atony and postpartum hemorrhage such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis. - Hepatic, renal, and cardiovascular disease.

Outcome

Primary Outcome Measures

1. Uterine Tone 2 minutes [2 minutes]

Intensity of uterine tone on a VNRS scale of 0-10 as evaluated by the obstetrician at 2 minutes after completion of injection of the bolus study drug.

Secondary Outcome Measures

1. Uterine Tone 5 minutes [5 minutes]

Intensity of uterine tone on a VNRS scale of 0-10 as evaluated by the obstetrician at 5 minutes after completion of injection of the bolus study drug.

2. Uterine Tone 10 minutes [10 minutes]

Intensity of uterine tone on a VNRS scale of 0-10 as evaluated by the obstetrician at 10 minutes after completion of injection of the bolus study drug.

3. Additional uterotonics - operating room [1 hour]

The use of additional uterotonic agents in the operating room

4. Additional uterotonics - 24 hours [24 hours]

The use of additional uterotonic agents at any time after admission to the recovery room and up to 24 hours post delivery

5. Estimated blood loss [24 hours]

Blood loss will be calculated through the difference in hematocrit values assessed prior to and at the end of 24 hours after the cesarean section.

6. Hypotension: systolic blood pressure less than 80% of baseline [2 hours]

Systolic blood pressure < 80% of baseline, from drug administration until end of surgery

7. Hypertension: systolic blood pressure greater than 120% of baseline [2 hours]

Systolic blood pressure > 120% of baseline, from drug administration until end of surgery

8. Tachycardia: heart rate greater than 130% of baseline [2 hours]

Heart rate > 130% of baseline, from drug administration until end of surgery

9. Bradycardia: heart rate less than 70% of baseline [2 hours]

Heart rate < 70% of baseline, from drug administration until end of surgery

10. Presence of ventricular tachycardia: ECG [2 hours]

Presence of ventricular tachycardia as recorded by ECG, from drug administration until end of surgery

11. Presence of atrial fibrillation: ECG [2 hours]

Presence of atrial fibrillation as recorded by ECG, from drug administration until end of surgery

12. Presence of atrial flutter: ECG [2 hours]

Presence of atrial flutter as recorded by ECG, from drug administration until end of surgery

13. Presence of nausea: questionnaire [2 hours]

The presence of nausea and number of episodes, from drug administration until end of surgery, as reported by the patient

14. Presence of vomiting: questionnaire [2 hours]

The presence of vomiting and number of episodes, from drug administration until end of surgery

15. Presence of chest pain: questionnaire [2 hours]

Any presence of chest pain, from drug administration until end of surgery, as reported by the patient

16. Presence of shortness of breath: questionnaire [2 hours]

Any presence of shortness of breath, from drug administration until end of surgery, as reported by the patient

17. Presence of headache: questionnaire [2 hours]

Any presence of headache, from drug administration until end of surgery, as reported by the patient

18. Presence of flushing: questionnaire [2 hours]

Any presence of flushing, from drug administration until end of surgery

Carbetocin vs. Oxytocin at Elective Cesarean Section

Keywords

attention deficit hyperactivity disorder

nausea

vomiting

hemorrhage

hypotension

postpartum hemorrhage